Business Information
The group's principal activity is to conduct research, develop and market products and services for the treatment of human diseases. The group uses the gene knockout technology to systematically discover the functions and pharmaceutical utility of genes in living mammals. The technology is applicable to therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. It alters the dna of genes in a special variety of mouse cells, called embryonic stem cells, which can be cloned and used to generate mice with the altered gene. Using this technology, the group discovers thousands of genes and expands its omnibank library of 200,000 frozen gene knockout es cell clones, each identified by dna sequence in a relational database. The omnibank library currently contains gene knockout clones for more than half of all genes in the mammalian genome.
|
|
Name |
Title
|
Email
|
| Alan Main | Exec. VP - Pharmaceutical Research | N/A | | Brian Zambrowicz | Chief Scientific Officer, Exec. VP | N/A | | James Piggott | Sr. VP - Pharmaceutical Biology | N/A | | Jeffrey Wade | Exec. VP, General Counsel | N/A | | Julia Gregory | CFO, Exec. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2005 | 75,680 | (36,315) | | 2004 | 61,740 | (47,172) | | 2003 | 42,838 | (64,198)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
